Articles published by argenx SE
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis
September 21, 2023
From argenx SE
Via GlobeNewswire
Tickers
ARGX
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
September 15, 2023
From argenx SE
Via GlobeNewswire
Tickers
ARGX
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
argenx to Present at Upcoming Investor Conferences
August 30, 2023
From argenx SE
Via GlobeNewswire
Tickers
ARGX
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update
July 27, 2023
From argenx SE
Via GlobeNewswire
Tickers
ARGX
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
argenx announces closing of global offering
July 24, 2023
From argenx SE
Via GlobeNewswire
Tickers
ARGX
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023
July 20, 2023
From argenx SE
Via GlobeNewswire
Tickers
ARGX
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
argenx announces launch of proposed global offering
July 17, 2023
From argenx SE
Via GlobeNewswire
Tickers
ARGX
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy
June 20, 2023
From argenx SE
Via GlobeNewswire
Tickers
ARGX
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
argenx to Present at Upcoming Investor Conferences
May 31, 2023
From argenx SE
Via GlobeNewswire
Tickers
ARGX
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023
April 27, 2023
From argenx SE
Via GlobeNewswire
Tickers
ARGX
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
April 17, 2023
From argenx SE
Via GlobeNewswire
Tickers
ARGX
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis
March 15, 2023
From argenx SE
Via GlobeNewswire
Tickers
ARGX
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update
March 02, 2023
From argenx SE
Via GlobeNewswire
Tickers
ARGX
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
argenx Appoints Steve Krognes to Board of Directors
February 27, 2023
From argenx SE
Via GlobeNewswire
Tickers
ARGX
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
argenx to Present at Upcoming Investor Conferences
February 27, 2023
From argenx SE
Via GlobeNewswire
Tickers
ARGX
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023
February 23, 2023
From argenx SE
Via GlobeNewswire
Tickers
ARGX
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
![](https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.